Mark H. N. Corrigan, MD

Formerly Chief Executive Officer, Correvio Pharma Corp.

Dr. Corrigan currently serves as a member of the board of directors of Nabriva Therapeutics plc, a publicly traded commercial-stage biopharmaceutical company. Dr. Corrigan also currently serves as chairman of the board of directors of Elios Therapeutics, LLC, a privately held development-stage immuno-oncology company. Dr. Corrigan previously served as the Chief Executive Officer of Correvio Pharma Corp. from March 2019 to May 2020, and served as President of Research and Development at Tremeau Pharmaceuticals (of which he is also a co-founder) from 2016 to March 2019, and continues to serve on its board of directors. Prior to the founding of Tremeau, he held several executive positions at Zalicus, Inc., Sepracor and Pharmacia Corp. Dr. Corrigan previously served as a member of the board of directors of Avanir Pharmaceuticals, Inc., CoLucid Pharmaceuticals, Inc., Correvio Pharma Corp., and Cubist Pharmaceuticals, Inc. Throughout his career, he personally led discovery and development efforts of multiple novel therapeutic approaches and has raised substantial capital through public markets to fund research, development and company operations. Dr. Corrigan is board certified in psychiatry and neurology and began his career as an Adjunct Professor in the Department of Psychiatry at the University of North Carolina. Dr. Corrigan holds a BA and a medical degree from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.